Sarah Kats, MD
Internal Medicine · Forest Hills, NYNPI 1073537502
Payments from drug & device makers
Across 122 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$658
- AbbVie$365
- GSK$189
- AstraZeneca$178
- Amgen$174
- Lilly USA, LLC$147
- plus $718 from 20 others
What the payments were for
- Food & beverage$2,40299%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $658 |
| AbbVie(2 entities) | 19 | $365 |
| GSK | 9 | $189 |
| AstraZeneca | 9 | $178 |
| Amgen(2 entities) | 10 | $174 |
| Lilly USA, LLC | 6 | $147 |
| Ardelyx, Inc. | 2 | $61 |
| Scilex Pharmaceuticals Inc. | 3 | $59 |
| Astellas Pharma US Inc | 2 | $58 |
| Nestle Healthcare Nutrition Inc. | 3 | $56 |
| Novo Nordisk | 2 | $55 |
| Pfizer | 3 | $51 |
| Amarin Pharma, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Bayer | 2 | $42 |
| Exact Sciences | 1 | $35 |
| Johnson & Johnson | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Corcept Therapeutics | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Vivus LLC | 1 | $18 |
| Bausch Health US, LLC | 1 | $15 |
How this compares
$2,430 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 117 | $62,998 |
| ZenpepLipase/Protease/Amylase | 26 | $60,228 |
| EliquisApixaban | 96 | $56,783 |
| OzempicSemaglutide | 41 | $39,808 |
| Diclofenac Sodium | 79 | $34,849 |
| JanuviaSitagliptin Phosphate | 59 | $31,207 |
| JardianceEmpagliflozin | 52 | $31,185 |
| TrulicityDulaglutide | 29 | $27,171 |
| ProliaDenosumab | 14 | $22,542 |
| FarxigaDapagliflozin Propanediol | 39 | $22,012 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $19,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $18,492 |
| TradjentaLinagliptin | 29 | $18,452 |
| VascepaIcosapent Ethyl | 54 | $17,853 |
| TrulancePlecanatide | 29 | $15,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Restasis, Synthroid | $365 | $81,041188 claims |
| PfizerEliquis, Premarin | $51 | $61,161107 claims |
| Novo NordiskOzempic | $55 | $39,80841 claims |
| Lilly USA, LLCTrulicity | $147 | $27,17129 claims |
| Johnson & JohnsonInvokana, Xarelto | $32 | $24,32744 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $189 | $22,98244 claims |
| AmgenProlia | $174 | $22,54214 claims |
| AstraZenecaFarxiga | $178 | $22,01239 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $658 | $15,73129 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $43 | $12,12723 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $7,73018 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $19 | $3,86016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Forest Hills
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.